Table 3.

Risk factors for the seroconversion of neutralizing antibody among BNT162b2 recipients.

	Adjusted OR *	95% CI
BNT162b2 (one dose) Day 21
Antibiotic usage	0.26	0.08–0.96
Age ≥ 60 years	0.34	0.13–0.95
Male sex	0.14	0.05–0.34
DM	0.42	0.12–1.66
Overweight/obesity	0.92	0.37–2.29
Hypertension	1.07	0.44–2.82
Raised LDL (≥3.4 mmol/L)	3.82	1.01–25.4
Smoking	1.14	0.22–9.40
Alcohol use	1.02	0.26–5.20
Moderate/severe hepatic steatosis (CAP ≥ 268 dB/M)	2.48	0.80–8.83
BNT162b2 (two doses) Day 56
Antibiotic usage	0.03	0.001–1.15
Age ≥ 60 years	0.38	0.006–69.18
Male sex	NA *	NA *
DM	0.02	0.0002–2.78
Overweight/obesity	0.58	0.008–27.85
Hypertension	0.40	0.008–25.06
Raised LDL (≥3.4 mmol/L)	0.56	0.01–101.48
Smoking	NA *	NA *
Alcohol use	NA *	NA *
Moderate/severe hepatic steatosis (CAP ≥ 268 dB/M)	NA *	NA *

* adjusted OR and 95% CI could not be derived due to the absence of negative serological response among all female patients, smokers, those who used alcohol and those with moderate/severe hepatic steatosis. Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; DM, diabetes mellitus; LDL, low density lipoprotein; CAP, controlled attenuated parameter.